Post-COVID in patients with immune-mediated inflammatory diseases: prospective multidimensional evaluation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028880

Enrollment

200

Registered

2022-06-14

Start date

2022-04-17

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K50.9 K51.9

Interventions

Group 1: Life-quality of patients with immune-mediated diseases will be assessed by standardized health questionnaires (SIBDQ, 5Q5DL). Furthermore, details regarding the comorbidities, medication and

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: - immune-mediated disease as established by experienced physiscian - willing to take part in the survey

Exclusion criteria

Exclusion criteria: - lack of cognitive ability to take part - acute SARS-CoV2-infection (proven/suspected)

Design outcomes

Primary

Measure	Time frame
Life-quality (SIBDQ; PHQ-4; EQ5D-DL; HAQ) differences in patients with survived COVID-19 against patients without diagnosed COVID-19 in a population with immune-mediated diseases. The questionnaire will be used once the patient is found eligible.	—

Secondary

Measure	Time frame
Post-COVID sysmptoms in relation to - age/gender - heigth/weight/BMI/nicotine consumption - leukocytes/CrP - mediacation - comorbidities - severitiy of COVID-19 - time and length of COVID-19 - autoimmune disease activity	—

Countries

Germany

Contacts

Public ContactTobias Schlosser

Universitätsklinik Leipzig AöR

tobias.schlosser@medizin.uni-leipzig.de00403419712400

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 6, 2026